FGFR2 and cholangiocarcinoma: The pan-FGFR inhibitor derazantinib (ARQ087) was firstly evaluated in a phase I/II study (AR087-101) enrolling 29 CCA patients with FGFR2 gene fusion [55]; most of the patients had experienced disease progression following at least one systemic treatment (n = 27), while two cases of treatment-naïve CCA were included.